| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/05/2022 | 178.45% | HC Wainwright & Co. | → $1.5 | Initiates Coverage On | → Buy |
| 11/01/2022 | 642.53% | Alliance Global Partners | → $4 | Initiates Coverage On | → Buy |
| 03/13/2020 | 828.16% | B. Riley Securities | $7 → $5 | Maintains | Buy |
| 03/29/2018 | 1385.06% | Canaccord Genuity | $15 → $8 | Maintains | Buy |
| 02/08/2018 | 456.9% | B. Riley Securities | → $3 | Initiates Coverage On | → Neutral |
What is the target price for Akari Therapeutics (AKTX)?
The latest price target for Akari Therapeutics (NASDAQ: AKTX) was reported by HC Wainwright & Co. on December 5, 2022. The analyst firm set a price target for $1.50 expecting AKTX to rise to within 12 months (a possible 178.45% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akari Therapeutics (AKTX)?
The latest analyst rating for Akari Therapeutics (NASDAQ: AKTX) was provided by HC Wainwright & Co., and Akari Therapeutics initiated their buy rating.
When is the next analyst rating going to be posted or updated for Akari Therapeutics (AKTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akari Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akari Therapeutics was filed on December 5, 2022 so you should expect the next rating to be made available sometime around December 5, 2023.
Is the Analyst Rating Akari Therapeutics (AKTX) correct?
While ratings are subjective and will change, the latest Akari Therapeutics (AKTX) rating was a initiated with a price target of $0.00 to $1.50. The current price Akari Therapeutics (AKTX) is trading at is $0.54, which is within the analyst's predicted range.